Spots Global Cancer Trial Database for The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Combination of PSMA-PET/MR and p2PSA in Early Diagnosis of Prostate Cancer
Official Title: The Combination of PSMA-PET/MRI and p2PSA in Early Diagnosis of Prostate Cancer
Study ID: NCT05822726
Interventions
Study Description
Brief Summary: This is a single center prospective non-randomized controlled study. The goal of this clinical trial is to figure out whether the combination of PSMA-PET/MR and PHI could add values to each method alone. The main questions it aims to answer are: * Compare the diagnostic value of the combination with each alone and set up a diagnostic model. * Compare the diagnostic value of PSMA-PET/MR+PHI to mpMRI+PHI. * Evaluate the diagnostic value the combination of PHI and PSMA-PET/MR in suspected PCA patients. Patients will experience mpMRI or PSMA-PET/MR and their blood samples will be used to test PSA and p2PSA. Prostate biopsy will be the golden standard.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
